1. 1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018 Nov; 68 (6): 394-424.
2. 2. The National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Colon Cancer. https://wwwnccnorg/professionals/physician_gls/pdf/colonpdf. 2020; version 4.
3. 3. Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. The EMBO journal. 1992 Nov; 11 (11): 3887-95.
4. 4. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer. The New England journal of medicine. 2017 Nov; 377 (20): 1919-29.
5. 5. Andre T SK-K, Kim TW. Pembrolizumab vs chemotherapy for microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: The phase 3 KEYNOTE-177 study. ASCO20 Virtual Scientific Program 2020; Abstract LBA4.